The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: A meta-analysis

CMAJ. Canadian Medical Association Journal

Volumn 180, Issue 2, 2009, Pages 183-193

  Henry, David ^a,d,e,f   Carless, Paul ^a   Fergusson, Dean ^b   Laupacis, Andreas ^c,d,e  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; APROTININ; PLACEBO; TRANEXAMIC ACID;

ARTICLE; BLEEDING; CLINICAL TRIAL; CONFIDENCE INTERVAL; DEATH; DRUG EFFICACY; EMBASE; ERYTHROCYTE TRANSFUSION; HEART INFARCTION; HEART SURGERY; HUMAN; MEDLINE; META ANALYSIS; REOPERATION; RISK; SYSTEMATIC REVIEW;

EID: 58849137661     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.081109     Document Type: Article

References (28)

1. Fergusson D, Blair A, Henry D, et al. Technologies to minimise blood transfusion in cardiac and orthopedic surgery: Results of a practice variation survey in ten countries. Int J Technol Assess Health Care 1999;15:717-28.
2. Henry DA, Carless PA, Moxey AJ, et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2007;(3):CD001886.
3. Sedrakyan A, Treasure T, Elefteriades J. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: A systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg 2004;128:442-8.
4. Munoz JJ, Birkmeyer NJO, Birkmeyer JD, et al. Is aminocaproic acid as effective as aprotinin in reducing bleeding with cardiac surgery? Circulation 1999;99:81-9.
5. Brown JR, Birkmeyer NJO, O'Connor GT. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation 2007;115:2801-13.
6. Carless PA, Moxey AJ, Stokes BJ. Are antifibrinolytic drugs equivalent in reducing blood loss and transfusion in cardiac surgery? A meta-analysis of randomized head-to-head trials. BMC Cardiovasc Disord 2005;5:19.
7. Ray WA, Stein CM. The aprotinin story - Is BART the final chapter? N Engl J Med 2008;358:2398-400.
8. Mangano DT, Miao Y, Vuylsteke A, et al. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA 2007;297:471-9.
9. Schneeweiss S, Seeger JD, Landon J, et al. Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med 2008;358:771-83.
10. Shaw AD, Stafford-Smith M, White WD, et al. The effect of aprotinin on outcome after coronary-artery bypass grafting. N Engl J Med 2008;358:784-93.
11. Levy JH, Ramsay JG, Guyton RA. Aprotinin in cardiac surgery. N Engl J Med 2006;354:1953-7.
12. Bidstrup BP. Aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion 2006;46:2208-10.
13. Fergusson DA, Hébert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008;358:2319-31.
14. Higgins J, Green S, editors. Cochrane handbook for systematic reviews of interventions: version 5.0.1 Oxford (UK): The Cochrane Collaboration; 2008. Available: www.cochrane.org/resources/handbook/index.htm (accessed 2008 Nov 26).
15. Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91.
16. Asimakopoulos G, Kohn A, Stefanou DC, et al. Leukocyte integrin expression in patients undergoing cardiopulmonary bypass. Ann Thorac Surg 2000;69:1192-7.
17. Cicekcioglu F, Cagli K, Emir M, et al. Effects of minimal dose aprotinin on blood loss and fibrinolytic system-complement activation in coronary artery bypass grafting surgery. J Card Surg 2006;21:336-41.
18. Wei M, Jian K, Guo Z, et al. Effects of half-dose aprotinin in off-pump coronary artery bypass grafting. World J Surg 2006;30:1108-14.
19. Feindt P, Seyfert U, Volkmer I, et al. Is there a phase of hypercoagulability when aprotinin is used in cardiac surgery? Eur J Cardiothorac Surg 1994;8:308-13.
20. Gott JP, Cooper WA, Schmidt FE, et al. Modifying risk for extracorporeal circulation: trial of four anti-inflammatory strategies. Ann Thorac Surg 1998;66:747-53.
21. Kuitunen AHS. Tranexamic acid does not correct the haemostatic impairment caused by hydroxyethyl starch (200 kDa/0.5) after cardiac surgery. Blood Coagul Fibrinolysis 2006;17:639-45.
22. Luo J, Huang Y, Lan H. Effect of aprotinin on the red cell immunity in cardiopulmonary bypass. J Tongji Med Univ 1998;18:97-100.
23. Rhydderch RD, Khan B, Saleh A, et al. Single dose aprotinin in routine cardiac surgery. Middle East J Anesthesiol 1993;12:287-97.
24. Murphy GJ, Mango E, Lucchetti V, et al. A randomized trial of tranexamic acid in combination with cell salvage plus a meta-analysis of randomized trials evaluating tranexamic acid in off-pump coronary artery bypass grafting. J Thorac Cardiovasc Surg 2006;132:475-80.
25. Parvizi R, Azarfarin R, Hassanzadeh S. Ultra-low dose aprotinin effects on reducing the need for blood transfusion in cardiac surgery. Saudi Med J 2007;28:49-53.
26. Lemmer JH Jr, Stanford W, Bonney SL, et al. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. A multicenter, randomized, double-blind, placebo-controlled study. J Thorac Cardiovasc Surg 1994;107:543-51.
27. Alderman EL, Levy JH, Rich JB, et al. Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. J Thorac Cardiovasc Surg 1998;116:716-30.
28. Mangano DT, Tudor IC, Dietzel C; Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006;354:353-65.